Vaccine Therapy in Treating Patients With Multiple Myeloma

NCT00019097 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Stage II Multiple Myeloma
Stage III Multiple Myeloma
Refractory Plasma Cell Neoplasm

Interventions

DRUG: autologous tumor cell vaccine
DRUG: keyhole limpet hemocyanin
DRUG: melphalan
DRUG: sargramostim

Sponsor

National Cancer Institute (NCI)